{"id":"W2559682469","doi":"10.1182/blood.v106.11.2556.2556","title":"A Phase I–II Trial of Bortezomib (Velcade) (Vc) and Oral Cyclophosphamide (CY) Plus Prednisone (P) for Relapsed/Refractory Multiple Myeloma (MM).","year":2005,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Thalidomide; Prednisone; Lenalidomide; Internal medicine; Gastroenterology; Regimen; Multiple myeloma; Melphalan; Cyclophosphamide; Refractory (planetary science); Surgery; Urology; Chemotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001619937,0.001082308,0.001244242,0.0003479422,0.0004367343,0.0007253174,0.0007196252,0.0007080474,0.003670841],"category_scores_gemma":[0.0006890374,0.0004948331,0.0006917123,0.0003527398,0.0008874036,0.0005523126,0.0003396677,0.002780851,0.0008226575],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006804834,"about_ca_system_score_gemma":0.0009265543,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0009473635,"about_ca_topic_score_gemma":0.002064244,"domain_scores_codex":[0.9995999,0.000219398,0.0000198904,0.00006016919,0.00002840267,0.00007229383],"domain_scores_gemma":[0.9994798,0.00009089072,0.00006151646,0.00003561987,0.00001453928,0.0003177191],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8135557,0.04845142,0.00508849,0.0005165086,0.0007791575,0.0005659525,0.0002240616,0.001871276,0.04161687,0.0003329442,0.005500353,0.08149734],"study_design_scores_gemma":[0.7148362,0.2676579,0.009161873,0.0000352073,0.0002698906,0.0003220853,0.00004422508,0.001067524,0.003100533,0.000182967,0.003303435,0.00001831028],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9924843,0.001996907,0.0004078723,0.0006008178,0.0002770379,0.001453284,0.0004867181,0.00006806856,0.002224999],"genre_scores_gemma":[0.9921102,0.001119757,0.0010214,0.0007111232,0.0002749238,0.001051625,0.001293514,0.00001580465,0.002401697],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003670841,"threshold_uncertainty_score":0.01228017,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03095290424956177,"score_gpt":0.3238474744655238,"score_spread":0.292894570215962,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}